{
  "title": "New Patient Outcome Assessed in Psoriasis Biologic Trial - Medscape",
  "url": "https://www.medscape.com/viewarticle/move-toward-assessing-well-being-psoriasis-biologic-2025a1000rgw",
  "summary": [
    {
      "type": "bullet",
      "text": "The POSITIVE trial uses patient-reported outcomes as a primary endpoint for the first time in evaluating psoriasis treatment with tildrakizumab."
    },
    {
      "type": "bullet",
      "text": "A 2-year follow-up showed significant improvement in psychological well-being (WHO-5 score) and reduction in Psoriasis Area and Severity Index (PASI), indicating overall better quality of life and mental health recovery beyond disease control."
    },
    {
      "type": "bullet",
      "text": "The trial highlights the importance of addressing both physical and mental health recovery, suggesting that patient-centered outcomes should be a key focus in evaluating therapeutic benefits for chronic diseases."
    }
  ],
  "model": "granite4:tiny-h"
}